Literature DB >> 7446204

Coronary ischaemia and occlusion in giant cell (temporal) arteritis.

J W Paulley.   

Abstract

Reports of coronary artery involvement in giant cell (temporal) arteritis--polymyalgia rheumatica (GC(T)A--PMR) together with other large arteries arising from the aorta have been numerous over the past 40 years, but on this the specialist cardiac literature has been virtually silent. This article summarises that evidence, and records nine additional patients from a large group of cases with both GC(T)A--PMR and ischaemic heart disease (IHD) observed since a previous report in 1960. The case histories illustrate the benefit from corticosteroids and the hazards of non-diagnosis and premature cessation of such treatment. It seems that many patients with arteritic IHD (and claudication) are not being identified before or after death. Possible reasons for this oversight by clinicians and pathologists are offered, and suggestions are made with regard to points in history-taking and important physical signs which may help to alert the clinician. There is autopsy evidence from Malmö, Sweden, that the prevalence of GC(T)A--PMR is much higher than at present suspected on clinical grounds.

Entities:  

Mesh:

Year:  1980        PMID: 7446204     DOI: 10.1111/j.0954-6820.1980.tb01190.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  4 in total

Review 1.  Giant cell arteritis.

Authors:  J M Calvo-Romero
Journal:  Postgrad Med J       Date:  2003-09       Impact factor: 2.401

2.  Life event research.

Authors:  J W Paulley
Journal:  Gut       Date:  1986-06       Impact factor: 23.059

3.  Giant cell (temporal) arteritis presenting with syncope.

Authors:  S H Cocksedge; A L Pozniak; A S Dixon
Journal:  Clin Rheumatol       Date:  1984-06       Impact factor: 2.980

4.  Severe cardiac failure and leukoerythroblastic anaemia in a patient with giant cell arteritis.

Authors:  R J Unwin; D J Carmichael; W S Peart
Journal:  J R Soc Med       Date:  1988-01       Impact factor: 18.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.